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Abstract
Objectives—To study the effects of reduced lipoic acid gene expression on diabetic
atherosclerosis in apolipoprotein E null mice (Apoe−/−).
Methods and Results—Heterozygous lipoic acid synthase gene knockout mice (Lias+/−)
crossed with Apoe−/− mice were used to evaluate the diabetic effect induced by streptozotocin on
atherosclerosis in the aortic sinus of the heart. While diabetes markedly increased atherosclerotic
plaque size in Apoe−/− mice, a small but significant effect of reduced expression of lipoic acid
gene was observed in diabetic Lias+/−Apoe−/− mice. In the aortic lesion area, the Lias+/−Apoe−/−
mice exhibited significantly increased macrophage accumulation and cellular apoptosis than
diabetic Lias+/+Apoe−/− littermates. Plasma glucose, cholesterol, and interleukin-6 were also
higher. These abnormalities were accompanied with increased oxidative stress including a
decreased ratio of reduced glutathione/oxidized glutathione in erythrocytes, increased systemic
lipid peroxidation, and increased Gpx1 and MCP1 gene expression in the aorta.
Conclusions—Decreased endogenous lipoic acid gene expression plays a role in development
of diabetic atherosclerosis. These findings extend our understanding of the role of antioxidant in
diabetic atherosclerosis.
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1. Introduction
Although type I diabetes is well recognized as a prevalent risk factor for cardiovascular
disease and atherosclerosis [1–3], the mechanism by which diabetes accelerates
atherosclerosis has not been clarified [4]. Accumulated evidence suggests that increased
production of reactive oxygen species (ROS) is a factor in diabetes associated
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atherosclerosis in murine models [2]. In addition, defective antioxidant defense has been
proposed as one of the mechanisms associated with type 1 diabetes [5].
Alpha-lipoic acid (1, 2-dithiolane-3-pentanoic acid; LA), generated by lipoic acid synthase
(Lias) in mitochondria, is an antioxidant and a cofactor for several mitochondrial enzymes
involved in glucose oxidation and ATP generation [6]. Lias homozygous embryos die in
utero, suggesting that LA is essential for energy metabolism in addition to its antioxidant
activity [7]. Lias+/− mice with around 50% Lias gene expression showed reduced
antioxidant defense against external stress [8]. We previously showed that dietary LA
supplementation in Apoe−/− mice decreased atherosclerotic lesion size [9] whereas genetic
reduction of Lias gene expression increased lesion size in Lias+/−Apoe−/− mice [10]. In the
present study, we expanded the previous studies by examining how a deficient antioxidant
defence in Lias+/−Apoe−/− mice contributed to atherosclerosis associated with type 1
diabetes. We aimed at further delineating the role of decreased endogenous antioxidant
capacity in the development of diabetic atherosclerosis. Our results show that diabetic
Lias+/−Apoe−/− mice with enhanced oxidative stress have increased atherosclerotic plaque
size and increased macrophage accumulation and cellular apoptosis in the lesion area.
2. Methods
Animals and experimental design
Apoe−/− mice on 129/SvEv background [11] were mated with Lias+/− mice on the same
background [7]. Mice were maintained on normal chow and on a twelve-hour light–dark
cycle in microisolator cages. Animal care and experimental protocols were approved by the
Institutional Animal Care and Use Committee of the University of North Carolina, Chapel
Hill. Two-month-old Lias+/−Apoe−/− (n=15) and Lias+/+Apoe−/− (n=17) male mice were
made diabetic by 5 daily intraperitoneal (i.p.) injections of streptozotocin (STZ, Sigma, St.
Louis) (40 mg/kg body weight) in 0.05 M sodium citrate buffer, pH 4.5. Control mice
(n=10, per genotype) received the citrate buffer alone. Animals with blood glucose levels
>300 mg/dL on day 2 after injection were included in this study. Blood glucose was
monitored for 4 months. The animals were sacrificed at 6 months of age.
Plasma analysis
After mice were fasted for 5 h, blood was collected from the retro-orbital sinus under
anesthesia. Plasma glucose, cholesterol and triglycerides were measured using the
commercial kits from Wako (Richmond, VA) according to the manufacturer’s protocols.
Plasma IL-6 was measured by ELISA (R&D Systems, Minneapolis, MN). Plasma
lipoproteins were fractionated using equal volumes of pooled plasma from each group of
animals on a Superose 6 fast protein liquid chromatography (FPLC) column (Amersham
Biosciences Biotech, Piscataway, NJ). The content of cholesterol in the eluted fractions was
measured with a microplate assay using enzymatic assay reagent kits obtained from Waco
(Richmond, VA).
Quantitation of atherosclerotic lesions
Mice were perfused with PBS containing heparin, followed by 4% buffered (pH 7.4)
paraformaldehyde under physiological pressure for routine histological analysis and by
buffered formalin (pH. 7.4) for immunohistochemical staining. The heart was then removed
and embedded in OCT compound. Cryosections (10 μm thick) were stained with Sudan IV
and counterstained with hematoxylin. The average lesion area from four anatomically
defined positions in sections was taken as the lesion size of each animal. The quantitative
morphometric analysis of lesion area using NIH 1.59 Imaging Software was carried out by a
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histologist blinded to the sample groups. For analysis of lesion composition; fibrous caps
and mast cells were stained with Masson’s trichrome and toluidine blue, respectively.
Oxidative stress biomarkers
The oxidative stress status of the whole body was determined by the ratio of GSH to GSSG
in erythrocytes using an assay kit (Calbiochem, San Diego, CA). Plasma lipid peroxide
content was determined using the thiobarbituric acid reactive substances (TBARS) assay
with malondialdehydeas as the standard [9]. 4-hydroxynonenal (4-HNE), a lipid
peroxidation marker, was assayed by using an ELISA Kit following the manufacturer’s
protocol (Cell Biolabs. Inc. San Diego, CA).
Measurement of apoptosis in aortic plaques
Apoptotic cells were identified by the terminal deoxynucleotidyl transferase dUTP nick end
labeling (TUNEL) method using a commercially available kit (Chemicon International Inc.
Billerica, MA) according to the manufacturer’s instructions, as previously described [10].
Samples in the absence of the TdT enzyme were used as negative controls. Slides were
sealed by cover slips with a DAPI-impregnated mounting medium (Southern Biotech;
Birmingham, AL).
Immunohistochemistry
Immunohistochemical analyses were performed on 10 μm frozen sections of aortic root.
Macrophages were detected using rat monoclonal anti-mouse MOMA-2 (Abcam,
Cambridge, MA) and rat monoclonal anti-mouse Mac-2 (Cedarlane, Burlington, NC) with
Cy5 conjugated to anti-rat IgG (Abcam). Sections were counterstained with DAPI. T-cells
were detected using rabbit polyclonal anti-human CD3 (Dako Cytomation). Endogenous
peroxidase activity was quenched with 3% H2O2/PBS. Secondary antibodies were
biotinylated conjugates that were subsequently detected using streptavidin-horseradish
peroxidase (HRP). Smooth muscle α-actin was detected using EPOS™ mouse anti-human
smooth muscle actin antibody coupled with HRP (DAKO). Bound antibodies were
visualized by incubation with 3, 3-diaminobenzidine tetrahydrochloride. Images were
viewed under an Olympus BX61 fluorescence microscope.
RT-PCR
Thoracic aortas were dissected from 6-month-old mice. Total RNA was isolated using an
ABI 6700 Automated Nucleic Acid Workstation following the manufacturer’s protocol
(Applied Biosystems, Foster City, CA). Expression of the genes for copper/zinc superoxide
dismutase (Sod1), manganese superoxide dismutase (Sod2), glutathione peroxidase (GPx1),
monocyte chemotactic protein-1 (MCP1), Lias, CD36 and smooth muscle α-actin were
determined by RT-PCR on an ABI prism 7700 sequence detection system (Applied
Biosystems, Foster City, CA). Samples from diabetic and non-diabetic mice were assayed in
the same 96-well plates for RT-PCR to compare relative expression levels. To analyze
mitochondrial function, liver gene expression of pyruvate dehydrogenase, citrate synthase,
cytochrome b and mitochondrial transcription factor A (mtTFA) were measured.
Urine albumin
Individual mice were housed in metabolic cages designed for mouse urine albumin excretion
determination. Body weight, food and water intake, and urine volume were monitored in a
24 h period for 2 consecutive days. Urine albumin was measured with a mouse Albuwell
ELISA kit (Exocell Inc. Philadelphia, PA).
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Statistical analysis was carried out using JMP software (SAS, Cary, NC). The effect of
diabetes and Lias gene expression and their interactions were analyzed using two-way
ANOVA, and the Tukey-Kramer honestly significant difference was used for multiple
comparisons. All data are represented as means ± standard error of means (SEM). P<0.05
values were considered to be statistically significant.
3. Results
Atherosclerosis in diabetic Lias+/−Apoe−/− mice
STZ-induced diabetes was associated with markedly increased atherosclerotic lesions
compared with non-diabetic mice. Quantitative morphometric analysis showed that lesion
size in diabetic Lias+/−Apoe−/− mice (32.4±26 x104μm2, n=16) was larger than that in the
diabetic Lias+/+Apoe−/− mice (23.9±23 x104μm2, n=15, p<0.05). Lesion size approximated
2.7 and 2.8-fold in Lias+/−Apoe−/− and Lias+/−Apoe−/− mice, respectively, compared to their
respective non-diabetic controls (Figure 1C). Lias heterozygosity also significantly
contributed to increased plaque size (Figure 1A, 1B). Two-way ANOVA analysis indicates
that diabetes and genotype were independent factors associated with increased lesion size
(P<0.001 for effect of diabetes, P<0.05 for effect of genotype, P=0.3 for interaction of two
variables).
We analyzed lesion composition because of its importance in the development and stability
of atherosclerotic lesions. Macrophage accumulation in aortic plaque area was noticeably
increased in diabetic Lias+/−Apoe−/− mice compared with diabetic Lias+/+Apoe−/− mice
(Figure 1D). Quantitative analysis of fluorescently stained Mac-2 or Moma-2 area relative to
total plaque area was significantly more in Lias+/−Apoe−/− mice (28.4±6.3%) than
Lias+/+Apoe−/− mice (9.0±2.1%) (P<0.05) (Figure 1E). T-lymphocytes, the major
inflammatory cells, also increased in diabetic Lias+/−Apoe−/− plaques (30±12%) compared
to Lias+/+Apoe−/− plaques (18±8%) although the difference was not statistically significant
P=0.09). Smooth muscle cell staining in the plaques was similar (diabetic; 15±4% for
Lias+/−Apoe−/− mice and 13±3% for Lias+/+Apoe−/− mice, P=0.12) (Supplemental Figure 1).
The thinnest part of fibrous caps (6.4±0.8 μm in diabetic Lias+/−Apoe−/− mice and 7.9±1.1
μm in diabetic Lias+/+Apoe−/− mice, P=0.23) and was measured following the method by
Teruyoshi Kume, et al., 2006 [12] and not significantly different. Degranulated mast cells
were only sparsely distributed in both diabetic genotypes (Supplemental Figure 1).
Apoptosis in aortic lesions
More than 90% of TUNEL-positive cells were located within macrophage-rich areas of the
intima. Lesions from diabetic Lias+/−Apoe−/− mice (Figure 1F) exhibited a significant
increase in intimal TUNEL positive cells relative to lesions from diabetic Lias+/+Apoe−/−
mice (Figure 1G).
Metabolic changes
Body weight and food intake markedly increased in diabetic mice but they did not
significantly differ between the two Lias genotypes (Table 1). To explore the mechanism by
which reduced Lias gene expression enhances atherosclerosis, we measured plasma glucose
and cholesterol content. In diabetic mice, the glucose levels of Lias+/−Apoe−/− mice (388±13
mg/dL) were significantly higher than those of Lias+/+Apoe−/− mice (344±15 mg/dL) at 6
months of age (For diabetic effect, P<0.001; for genotype effect, P<0.01; for interaction,
P=0.14) (Figure 2). Likewise, the cholesterol levels of Lias+/−Apoe−/− mice (831±30 mg/dL)
were significantly higher than those of Lias+/+Apoe−/− mice (712±27 mg/dL), P<0.01 for
diabetic effect, P<0.001 for genotype effect, and P=0.83 for interaction (Figure 3A and
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Table 1). Plasma triglyceride levels sho wed similar trends, but neither diabetic nor
genotypic effects were significant (Figure 3B and Table 1). The increase in plasma
cholesterol observed in diabetic mice was confined to VLDL, IDL and LDL fractions of
FPLC. VLDL and IDL cholesterol fractions increased in diabetic Lias+/−Apoe−/− compared
to diabetic Lias+/+Apoe−/− mice (Figure 3C). Although STZ treated animals displayed
higher HDL level, they were not significantly different from non-STZ groups.
Oxidative stress
We next examined whether the increased atherosclerotic lesion size is accompanied by a
changed redox balance. The ratio of GSH to GSSH in erythrocytes in diabetic
Lias+/−Apoe−/− mice was significantly lower than the ratio in diabetic Lias+/+Apoe−/− mice
(P<0.05) (Figure 4 and table 1). This suggests that diabetic Lias+/−Apoe−/− mice experienced
increased oxidative stress. Two-way ANOVA analysis indicates that diabetes and genotype
serve as mutually independent factors to decrease the ratios of GSH to GSSH (P<0.05 for
diabetes effect, P<0.05 for genotype effect, and P=0.7 for interaction). Plasma TBARs in
non-diabetic mice was significantly higher in Lias+/−Apoe−/− than in Lias+/+Apoe−/− mice.
Diabetes increased TBARs levels in both genotypes, but TBARs increased more in diabetic
Lias+/+Apoe−/− mice leading to no significant difference between two diabetic groups
(P=0.055). In non-diabetic mice, 4-hydroxynonenal (4-HNE) in both aortic and renal tissues
showed significantly higher levels in Lias+/−Apoe−/− genotype. 4-HNE levels increased by
about 2 fold in the diabetic tissues. However, 4-HNE increased less in Lias+/−Apoe−/− aorta
than Lias+/+Apoe−/− aorta, resulting in a non-significant difference between the two
genotypes (Figure 4). In contrast, 4-HNE was significantly higher in diabetic Lias+/−Apoe−/−
kidney (P<0.05).
Aortic and liver gene expression
Lias gene expression was significantly lower in Lias+/− heterozygote (P<0.01) and diabetes
decreased further (P<0.01) (Table 2). The effect of the two factor was independent
(interaction, P=0.55) but Lias+/−Apoe−/− mice had only 20% of Lias gene expression
compared to that in diabetic Lias+/+Apoe−/− mice. Diabetes increased GPx1 gene expression
significantly (P<0.001) in both diabetic Lias+/−Apoe−/− and Lias+/+Apoe−/− mice (Table 2A)
(diabetic effect, P<0.001 and genotype effect, P<0.05). In contrast, both Sod1 and Sod2
gene expression were lower in Lias+/+Apoe−/− mice than in Lias+/−Apoe−/− mice, and
diabetes affected their expressions only slightly. MCP-1 gene expression was higher in
Lias+/−Apoe−/− aortas (P<0.05) and diabetes further increased in both genotypes (P<0.05)
(Table 2A). CD36 and smooth muscle α-actin gene expression were elevated in diabetic
Lias+/−Apoe−/− mice compared to diabetic Lias+/+Apoe−/− mice but they were not
statistically different (Table 2A). To examine mitochondrial function, we analyzed
expression of mitochondrial enzymes and mtTFA in the livers of diabetic mice. Pyruvate
dehydrogenase and citrate synthase gene expression were significantly lower in diabetic
Lias+/−Apoe−/− mice than diabetic Lias+/+Apoe−/− mice. Cytochrome b and mtTFA
expression showed no significance between the two genotypes (Table 2B).
Inflammation
In non-diabetic mice, serum IL-6 in Lias+/−Apoe−/− was slightly higher than Lias+/+Apoe−/−
mice although the difference was not significant. However, IL-6 levels in diabetic mice were
significantly elevated (P<0.001). P<0.05 for interaction of two variables by two-way
ANOVA indicates that the diabetic effect was more pronounced in Lias+/−Apoe−/− mice
than in Lias+/+Apoe−/− mice (Figure 5).
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Kidney damage by oxidative stress
To determine susceptibility of the aorta and the kidney to oxidative stress and whether
diabetic atherosclerosis was correlated with diabetic kidney disease, we examined daily
urine albumin excretion in 6-month-old diabetic mice. Albuminuria was significantly higher
in Lias+/−Apoe−/− mice than in Lias+/+Apoe−/− mice (Table 1). However, although urine
albumin and atherosclerotic lesion size were increased in diabetes, there was no correlation
between them in individual animals (data not shown).
4. Discussion
Our previous results have demonstrated that Lias+/− mice with 50% Lias gene expression
developed ~1.5-fold enhanced atherosclerotic lesion size with a concomitant significant
increase in plasma and tissue oxidative stress in non-diabetic male Lias+/−Apoe−/− mice
[10]. Current studies show that induction of diabetes in mice by STZ treatment increased
atherosclerotic lesion size in both genotypic groups, and diabetes and Lias heterozygosity
contributed additively.
The genotypic effect may involve the following events: First, oxidative stress was involved
in enhanced diabetic atherosclerotic development. Our data show that antioxidant capacity
indicated by the ratio of erythrocyte GSH to GSSG in diabetic mice declined compared with
the non-diabetic mice. In addition, Lias gene expression in diabetic Lias+/−Apoe−/− mice
dropped to 20% of non-diabetic Lias+/+Apoe−/− controls. Furthermore, aortic Gpx-1 gene
expression was up-regulated in the diabetic mice, and significantly enhanced in diabetic
Lias+/−Apoe−/− mice as a physiological response to oxidation [13]. Moreover, the number of
macrophages co-localizing with apoptotic cells were increased in the plaques of diabetic
Lias+/−Apoe−/− mice as compared to diabetic Lias+/+Apoe−/− mice. The result suggests that
LA may target macrophage directly as a recent paper shows that LA inhibited foam cell
formation [14]. On the other hand, the antioxidant capacity was limited. The endogenous
antioxidant capacity is likely exhausted after being stressed by a combination of both
atherosclerosis and diabetes in diabetic Lias+/+Apoe−/− mice. This possibility is supported
by the observation that plasma TBARs and gene expression of two important aortic
antioxidant enzymes, Sod1 and Sod2, was reduced further in diabetic Lias+/+Apoe−/− mice
than in diabetic Lias+/−Apoe−/− mice.
Second, the metabolic effect and potential mitochondrial protection of lipoic acid deficiency
likely exacerbates atherosclerosis. It is very likely that LA, as a cofactor for several
mitochondrial enzyme complexes, participates in metabolic reactions that contribute to
reduce plasma cholesterol [9, 15], triglyceride [16] and body weight [17]. In addition, we
previously showed that the dietary LA supplementation may accelerate the recovery of
pancreatic beta-cells after STZ treatment [9]. Higher plasma glucose levels at 6 months in
Lias+/−Apoe−/− mice than in Lias+/+Apoe−/− mice may therefore indicate increased recovery
from diabetes. This is also consistent with the previous data that diabetic Lias+/−Apoe−/−
mice had significantly higher plasma cholesterol than diabetic Lias+/+Apoe−/− mice [10]. On
the other hand, our RT-PCR data results showed a significant reduction in the expression of
two mitochondrial enzymes, pyruvate dehydrogenase and citrate synthase in diabetic
Lias+/−Apoe−/− mice compared to diabetic Lias+/+Apoe−/− mice. The result implies that
mitochondrial function was impaired. However, two other mitochondrial genes, cytochrome
b and mtTFA, were not significantly different between the two genotypic mice, suggesting
that the number of mitochondria and biogenesis are likely unaffected.
Finally, higher inflammation levels in the diabetic Lias heterozygotes likely exacerbate
atherosclerosis. Studies have shown that type 1 diabetes is pro-inflammatory [18, 19], and
inflammation is a major pathogenic factor contributing to the development of atherosclerosis
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[20]. Recent studies demonstrate association of increased systemic IL-6 levels with incidents
of coronary heart disease [21]. We found that the pro-inflammatory cytokine, IL-6, was
significantly increased in diabetic mice, especially Lias+/−Apoe−/− mice, compared to
Lias+/+Apoe−/− mice (P<0.01). Increased inflammatory response of Lias+/− mice is
consistent with our previous observation that Lias+/− mice have a markedly enhanced
inflammatory response after administration of lipopolysaccharide [8]. Zhang et al., [16]
described that LA inhibits atherosclerosis in Apoe−/− mice through its anti-inflammatory
effect. IL-6 can induce expression of MCP-1 [22] that plays a pivotal role in trafficking of
monocytes into aortic walls. Our data showed increased gene expression of aortic MCP-1,
which may be responsible for increased macrophage in the plaques.
In conclusion, we have used genetic techniques to demonstrate that decreased antioxidant
capacity exacerbates diabetes-associated atherosclerosis. These findings extend our
understanding of the role of antioxidants in diabetic atherosclerosis.
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• We evaluate effects of reduced lipoic acid synthase gene expression on diabetic
atherosclerosis.
• Apolipoiprotein E null mice were crossed with Lias antioxidant model and then
induced to diabetes.
• Reduced endogenous lipoic acid capacity plays a role in development of
diabetic atherosclerosis.
• These findings extend our understanding of the role of antioxidant in diabetic
atherosclerosis.
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Representative photomicrographs of the aortic sinus plaque in Lias+/−Apoe−/− mice (A) and
Lias+/+Apoe−/− mice (B) at 4 months after streptozotocin(STZ)-induced diabetes. Lesions
are shown in red, after Sudan IV staining to detect lipids. Magnification X40. (C) Plaque
area within the aortic sinus in Lias+/−Apoe−/− mice (black circles) and Lias+/+Apoe−/− mice
(open circles) 6 months after streptozotocin induced diabetes. Each dot indicates the average
lesion size of 4 sections in each mouse. Horizontal bars with numbers indicate logarithm.
The number under the dots indicates animal numbers per group. (D) Macrophage infiltration
into atherosclerotic lesions was increased in Lias+/−Apoe−/− mice. Representative
photographs of MOMA-2 immunostaining of aortic root sections. Macrophages were stained
with MOMA-2 antibody (red). Cell nuclei were stained with DAPI (blue). Two aortic
sections were examined per mouse, three mice per group. Scale bar indicates 100 μm. (E)
Quantification of MOMA-positive area relative to plaque area. Original magnification x40.
(F) Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) staining in
aorta of Lias+/−Apoe−/− and Lias+/+Apoe−/− mice. The TUNEL stain was colocalized with or
very close to nuclei stained with DAPI. (G) The percentage of aortic lesions that had
TUNEL-positive regions. Scale bar indicates 100 μm. Original magnification x40.
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Blood glucose changes in Lias+/−Apoe−/− mice (black circles) and Lias+/+Apoe−/− mice
(open circles) during the study period. All mice were injected with STZ at 2 months of age.
The number of animals in each group is in the parentheses. Data are the mean ± SEM. *
indicates P<0.05.
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Plasma cholesterol (A) and triglyceride levels (B) in diabetic Lias+/+Apoe−/− mice (open
bars) and diabetic Lias+/−Apoe−/− mice (black bars). Results are expressed as means ± SEM.
(C) FPLC of plasma from diabetic and non-diabetic Lias+/−Apoe−/− and Lias+/+Apoe−/−
mice. Equal volumes of plasma from the mice at 6 months old were pooled and subjected to
gel filtration chromatography. Eluted fractions (0.5 ml) were collected, and cholesterol
concentrations were measured as described in methods. VLDL, very-low-density
lipoproteins; IDL, intermediate density lipoprotein; LDL, low-density lipoproteins; HDL,
high-density lipoproteins.
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(A) Ratios of reduced/oxidized glutathione (GSH/GSSG) of erythrocytes. (B) Plasma
thiobarbituric acid reactive substances (TBARS). (C) 4-hydroxynonenal (4-HNE) in aorta
and kidney cortex in Lias+/−Apoe−/− (black bars) and Lias+/+Apoe−/− mice (open bars). The
numbers inside bars indicate number of animals. Results are expressed as mean ± SEM.
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Plasma IL-6 measured by ELISA in Lias+/−Apoe−/− mice (black bars) and
Lias+/−Apoe−/+mice (open bars). Values are expressed as mean ± SEM.
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